[Comment] CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma

Marginal zone lymphoma (MZL) is an indolent B-cell malignancy that accounts for approximately 7% of mature non-Hodgkin lymphomas.1 It is characterised by varied anatomical and clinical features across nodal, splenic, and extranodal or mucosa-associated lymphoid tissue subtypes.2 For relapsed or refractory MZL, standard options include anti-CD20-based regimens, lenalidomide–rituximab, and Bruton tyrosine kinase inhibitors (BTKis).3 However, the achievement of deep and durable remissions remains challenging.